naluzotan and Depressive-Disorder--Major

naluzotan has been researched along with Depressive-Disorder--Major* in 1 studies

Reviews

1 review(s) available for naluzotan and Depressive-Disorder--Major

Article	Year
Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:1 EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007. Topics: Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Molecular Structure; Piperazines; Serotonin 5-HT1 Receptor Agonists; Smoking Cessation; Sulfonamides	2007

Article

Year

Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:1

EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007.

Topics: Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Molecular Structure; Piperazines; Serotonin 5-HT1 Receptor Agonists; Smoking Cessation; Sulfonamides

2007